Self-Reported Management of Inflammatory Breast Cancer Among the American Society of Breast Surgeons Membership: Consensus and Opportunities.
American Society of Breast Surgeons
Inflammatory breast cancer
Surgical de-escalation
Trimodal therapy
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
21 Jul 2024
21 Jul 2024
Historique:
received:
19
04
2024
accepted:
29
05
2024
medline:
22
7
2024
pubmed:
22
7
2024
entrez:
21
7
2024
Statut:
aheadofprint
Résumé
Inflammatory breast cancer (IBC) is rare and biologically aggressive. We sought to assess diagnostic and management strategies among the American Society of Breast Surgeons (ASBrS) membership. An anonymous survey was distributed to ASBrS members from March to May 2023. The survey included questions about respondents' demographics and information related to stage III and IV IBC management. Agreement was defined as a shared response by >80% of respondents. In areas of disagreement, responses were stratified by years in practice, fellowship training, and annual IBC patient volume. The survey was administered to 2337 members with 399 (17.1%) completing all questions and defining the study cohort. Distribution of years in practice was 26.0% 0-10 years, 26.6% 11-20 years and 47.4% > 20 years. Overall, 51.2% reported surgical oncology or breast fellowship training, 69.2% maintain a breast-only practice, and 73.5% treat < 5 IBC cases/year. Agreement was identified in diagnostic imaging, trimodal therapy, and mastectomy with wide skin excision for stage III IBC. Lack of agreement was identified in surgical management of the axilla; respondents with < 10 years in practice or fellowship training were more likely to perform axillary dissection for cN0-N2 stage III IBC. Locoregional management of stage IV IBC was variable. Among ASBrS members, there is consensus in diagnostic evaluation, treatment sequencing and surgical approach to the breast in stage III IBC. Differences exist in surgical management of the cN0-2 axilla with uptake of de-escalation strategies. Clinical trials are needed to evaluate oncologic safety of de-escalation in this high-risk population.
Sections du résumé
BACKGROUND
BACKGROUND
Inflammatory breast cancer (IBC) is rare and biologically aggressive. We sought to assess diagnostic and management strategies among the American Society of Breast Surgeons (ASBrS) membership.
PATIENTS AND METHODS
METHODS
An anonymous survey was distributed to ASBrS members from March to May 2023. The survey included questions about respondents' demographics and information related to stage III and IV IBC management. Agreement was defined as a shared response by >80% of respondents. In areas of disagreement, responses were stratified by years in practice, fellowship training, and annual IBC patient volume.
RESULTS
RESULTS
The survey was administered to 2337 members with 399 (17.1%) completing all questions and defining the study cohort. Distribution of years in practice was 26.0% 0-10 years, 26.6% 11-20 years and 47.4% > 20 years. Overall, 51.2% reported surgical oncology or breast fellowship training, 69.2% maintain a breast-only practice, and 73.5% treat < 5 IBC cases/year. Agreement was identified in diagnostic imaging, trimodal therapy, and mastectomy with wide skin excision for stage III IBC. Lack of agreement was identified in surgical management of the axilla; respondents with < 10 years in practice or fellowship training were more likely to perform axillary dissection for cN0-N2 stage III IBC. Locoregional management of stage IV IBC was variable.
CONCLUSIONS
CONCLUSIONS
Among ASBrS members, there is consensus in diagnostic evaluation, treatment sequencing and surgical approach to the breast in stage III IBC. Differences exist in surgical management of the cN0-2 axilla with uptake of de-escalation strategies. Clinical trials are needed to evaluate oncologic safety of de-escalation in this high-risk population.
Identifiants
pubmed: 39034365
doi: 10.1245/s10434-024-15713-y
pii: 10.1245/s10434-024-15713-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Society of Surgical Oncology.
Références
Adesoye T, Lucci A. Current surgical management of inflammatory breast cancer. Ann Surg Oncol. 2021;28(10):5461–7. https://doi.org/10.1245/s10434-021-10522-z .
doi: 10.1245/s10434-021-10522-z
pubmed: 34346020
Matro JM, Li T, Cristofanilli M, et al. Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome. Clin Breast Cancer. 2015;15(1):1–7.
doi: 10.1016/j.clbc.2014.05.005
pubmed: 25034439
Warren LE, Guo H, Regan MM, et al. Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. Breast Cancer Res Treat. 2015;151(1):225–32.
doi: 10.1007/s10549-015-3381-8
pubmed: 25893587
Dawood S, Ueno NT, Valero V, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. 2011;117(9):1819–26.
doi: 10.1002/cncr.25682
pubmed: 21509759
Jagsi R, Mason G, Overmoyer BA, et al. Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research. Breast Cancer Res Treat. 2022;192(2):235–43.
doi: 10.1007/s10549-021-06434-x
pubmed: 34973083
pmcid: 8926970
Lynce F, Niman S, Kai M, et al. Development of a multi-institutional, photograph-rich clinical dataset to test and validate a novel inflammatory breast cancer (IBC) scoring system. Paper presented at: San Antonio Breast Cancer Symposium2023; San Antonio, Texas.
Network NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 5.2021 - 2021.
Adesoye T, Everidge S, Chen J, et al. Low rates of local-regional recurrence among inflammatory breast cancer patients after contemporary trimodal therapy. Ann Surg Oncol. 2023;30(10):6232–40.
doi: 10.1245/s10434-023-13906-5
pubmed: 37479842
Thoms WW Jr, McNeese MD, Fletcher GH, Buzdar AU, Singletary SE, Oswald MJ. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1989;17(4):739–45.
doi: 10.1016/0360-3016(89)90060-6
pubmed: 2487034
Rehman S, Reddy CA, Tendulkar RD. Modern outcomes of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2012;84(3):619–24.
doi: 10.1016/j.ijrobp.2012.01.030
pubmed: 22445003
Rosso KJ, Tadros AB, Weiss A, et al. Improved locoregional control in a contemporary cohort of nonmetastatic inflammatory breast cancer patients undergoing surgery. Ann Surg Oncol. 2017;24(10):2981–8. https://doi.org/10.1245/s10434-017-5952-x .
doi: 10.1245/s10434-017-5952-x
pubmed: 28766220
Cristofanilli M, Valero V, Buzdar AU, et al. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007;110(7):1436–44.
doi: 10.1002/cncr.22927
pubmed: 17694554
Brzezinska M, Williams LJ, Thomas J, Michael Dixon J. Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery. Breast Cancer Res Treat. 2016;160(3):387–91.
doi: 10.1007/s10549-016-4017-3
pubmed: 27757718
Postlewait LM, Teshome M, Adesoye T, et al. Contralateral axillary metastasis in patients with inflammatory breast cancer. Ann Surg Oncol. 2021;28(13):8610–21. https://doi.org/10.1245/s10434-021-10148-1 .
doi: 10.1245/s10434-021-10148-1
pubmed: 34125346
Fayanju OM, Ren Y, Greenup RA, et al. Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. Breast Cancer Res Treat. 2020;180(1):207–17.
doi: 10.1007/s10549-020-05529-1
pubmed: 31960171
pmcid: 7050768
Kupstas AR, Hoskin TL, Day CN, Boughey JC, Habermann EB, Hieken TJ. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database. Br J Surg. 2020;107(8):1033–41.
doi: 10.1002/bjs.11469
pubmed: 32057107
Chen H, Wu K, Wang M, Wang F, Zhang M, Zhang P. A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: a large population-based study in the Surveillance, Epidemiology, and End Results database 18. Breast. 2017;35:48–54.
doi: 10.1016/j.breast.2017.06.002
pubmed: 28649032
Romanoff A, Zabor EC, Petruolo O, et al. Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers? Cancer. 2018;124(22):4314–21.
doi: 10.1002/cncr.31757
pubmed: 30307616
Nakhlis F, Regan MM, Warren LE, et al. The impact of residual disease after preoperative systemic therapy on clinical outcomes in patients with inflammatory breast cancer. Ann Surg Oncol. 2017;24(9):2563–9. https://doi.org/10.1245/s10434-017-5903-6 .
doi: 10.1245/s10434-017-5903-6
pubmed: 28560598
Rueth NM, Lin HY, Bedrosian I, et al. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. J Clin Oncol. 2014;32(19):2018–24.
doi: 10.1200/JCO.2014.55.1978
pubmed: 24888808
pmcid: 4067942
Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol. 2002;9(3):235–42. https://doi.org/10.1007/BF02573060 .
doi: 10.1007/BF02573060
pubmed: 11923129
Hidar S, Bibi M, Gharbi O, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer. Int J Surg. 2009;7(3):272–5.
doi: 10.1016/j.ijsu.2009.04.012
pubmed: 19410665
Karanlik H, Cabioglu N, Oprea AL, et al. Sentinel lymph node biopsy may prevent unnecessary axillary dissection in patients with inflammatory breast cancer who respond to systemic treatment. Breast Care (Basel). 2021;16(5):468–74.
doi: 10.1159/000512202
pubmed: 34720806
DeSnyder SM, Mittendorf EA, Le-Petross C, et al. Prospective feasibility trial of sentinel lymph node biopsy in the setting of inflammatory breast cancer. Clin Breast Cancer. 2018;18(1):e73–7.
doi: 10.1016/j.clbc.2017.06.014
pubmed: 28755879
Farley CR, Irwin S, Adesoye T, et al. Lymphedema in inflammatory breast cancer patients following trimodal treatment. Ann Surg Oncol. 2022;29(10):6370–8. https://doi.org/10.1245/s10434-022-12142-7 .
doi: 10.1245/s10434-022-12142-7
pubmed: 35854031
Coriddi M, Dayan J, Bloomfield E, et al. Efficacy of immediate lymphatic reconstruction to decrease incidence of breast cancer-related lymphedema: preliminary results of randomized controlled Trial. Ann Surg. 2023;278(4):630–7.
doi: 10.1097/SLA.0000000000005952
pubmed: 37314177
Simpson AB, McCray D, Wengler C, et al. Immediate reconstruction in inflammatory breast cancer: challenging current care. Ann Surg Oncol. 2016;23(Suppl 5):642–8. https://doi.org/10.1245/s10434-016-5554-z .
doi: 10.1245/s10434-016-5554-z
pubmed: 27638670
Nakhlis F, Regan MM, Chun YS, et al. Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: the Dana-Farber Cancer Institute’s Inflammatory Breast Cancer Program experience. Breast J. 2020;26(3):384–90.
doi: 10.1111/tbj.13509
pubmed: 31448540
Khan SA, Zhao F, Goldstein LJ, et al. Early local therapy for the primary site in de novo stage IV breast cancer: results of a randomized clinical trial (EA2108). J Clin Oncol. 2022;40(9):978–87.
doi: 10.1200/JCO.21.02006
pubmed: 34995128
pmcid: 8937009
Akay CL, Ueno NT, Chisholm GB, et al. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer. 2014;120(9):1319–28.
doi: 10.1002/cncr.28550
pubmed: 24510381
Partain N, Postlewait LM, Teshome M, et al. The role of mastectomy in de novo stage IV inflammatory breast cancer. Ann Surg Oncol. 2021;28(8):4265–74.
doi: 10.1245/s10434-020-09392-8
pubmed: 33403525
Dawood S, Ueno NT, Valero V, et al. Identifying factors that impact survival among women with inflammatory breast cancer. Ann Oncol. 2012;23(4):870–5.
doi: 10.1093/annonc/mdr319
pubmed: 21765048
van Uden DJP, van Maaren MC, Strobbe LJA, et al. Better survival after surgery of the primary tumor in stage IV inflammatory breast cancer. Surg Oncol. 2020;33:43–50.
doi: 10.1016/j.suronc.2020.01.005
pubmed: 32561098
Díaz-Roldán J, Eguía-Larrea M, Rubio-Sánchez T, Muñoz-Bellvís L. Systematic review of synchronous contralateral axillary metastases in breast cancer: really M1 disease? Breast Cancer. 2022;29(1):9–18.
doi: 10.1007/s12282-021-01293-2
pubmed: 34652689